For example, activation of β2-adrenoreceptor signaling delays the loss of MCL1 protein expression and increases resistance of prostate cancer xenografts to cytotoxic therapies [44], and inhibition of HAX-1 by microRNA-125a significantly promotes cisplatin-induced apoptosis in laryngeal cancer stem cells and reduces resistance to various chemotherapeutic agents, including doxorubicin [45]. This evidence concerns the gene MCL1 and prostate cancer.